JP2015516975A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516975A5 JP2015516975A5 JP2015507076A JP2015507076A JP2015516975A5 JP 2015516975 A5 JP2015516975 A5 JP 2015516975A5 JP 2015507076 A JP2015507076 A JP 2015507076A JP 2015507076 A JP2015507076 A JP 2015507076A JP 2015516975 A5 JP2015516975 A5 JP 2015516975A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inhibitor
- influenza
- ttsp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000003112 inhibitor Substances 0.000 claims 9
- 108091005804 Peptidases Proteins 0.000 claims 6
- 239000004365 Protease Substances 0.000 claims 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 6
- 206010022000 influenza Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 101710154606 Hemagglutinin Proteins 0.000 claims 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 2
- 101710176177 Protein A56 Proteins 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000000185 hemagglutinin Substances 0.000 claims 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 1
- 229940124873 Influenza virus vaccine Drugs 0.000 claims 1
- 241001500351 Influenzavirus A Species 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 210000001132 alveolar macrophage Anatomy 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 229960003752 oseltamivir Drugs 0.000 claims 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 229960000888 rimantadine Drugs 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 229960001028 zanamivir Drugs 0.000 claims 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624519P | 2012-04-16 | 2012-04-16 | |
| US61/624,519 | 2012-04-16 | ||
| US201361759469P | 2013-02-01 | 2013-02-01 | |
| US61/759,469 | 2013-02-01 | ||
| PCT/US2013/036522 WO2013158516A1 (en) | 2012-04-16 | 2013-04-15 | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017203146A Division JP2018048169A (ja) | 2012-04-16 | 2017-10-20 | セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516975A JP2015516975A (ja) | 2015-06-18 |
| JP2015516975A5 true JP2015516975A5 (enExample) | 2016-05-19 |
| JP6446355B2 JP6446355B2 (ja) | 2018-12-26 |
Family
ID=48184523
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507076A Active JP6446355B2 (ja) | 2012-04-16 | 2013-04-15 | セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法 |
| JP2017203146A Withdrawn JP2018048169A (ja) | 2012-04-16 | 2017-10-20 | セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017203146A Withdrawn JP2018048169A (ja) | 2012-04-16 | 2017-10-20 | セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9498529B2 (enExample) |
| EP (2) | EP2838558A1 (enExample) |
| JP (2) | JP6446355B2 (enExample) |
| KR (1) | KR20150008383A (enExample) |
| CN (1) | CN104244978A (enExample) |
| AU (2) | AU2013249577A1 (enExample) |
| BR (1) | BR112014025339A8 (enExample) |
| CA (2) | CA3219083A1 (enExample) |
| HK (1) | HK1202817A1 (enExample) |
| MX (1) | MX2014012285A (enExample) |
| NZ (1) | NZ631105A (enExample) |
| SG (1) | SG11201405163RA (enExample) |
| WO (1) | WO2013158516A1 (enExample) |
| ZA (1) | ZA201406194B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3895529B1 (en) | 2016-02-29 | 2026-04-29 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized tmprss gene |
| KR101693243B1 (ko) * | 2016-06-15 | 2017-01-05 | 재단법인 한국파스퇴르연구소 | 인플루엔자 바이러스의 복제에 관여하는 신규 인간 유전자 및 이의 용도 |
| BR112020015112A2 (pt) * | 2018-01-26 | 2021-04-06 | Regeneron Pharmaceuticals, Inc. | Anticorpos anti-tmprss2 e fragmentos que ligam antígenos |
| EP4103619A1 (en) * | 2020-02-10 | 2022-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss2 antibodies and antigen-binding fragments |
| WO2021190980A1 (en) | 2020-03-22 | 2021-09-30 | Quadrucept Bio Limited | Multimers for viral strain evolution |
| WO2021195119A1 (en) * | 2020-03-24 | 2021-09-30 | Corcept Therapeutics Incorporated | Methods of reducing the risk of, severity of, and treating coronavirus infections |
| EP3964207A1 (en) | 2020-09-02 | 2022-03-09 | Christian-Albrechts-Universität zu Kiel | Antiviral pharmaceutical composition for topical administration |
| WO2022184659A1 (en) | 2021-03-01 | 2022-09-09 | Quadrucept Bio Limited | Antibody domains & multimers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000000605A1 (en) * | 1998-06-29 | 2000-01-06 | Myriad Genetics, Inc. | Tmprss2 is a tumor suppressor |
| WO2004097358A2 (en) | 2003-05-02 | 2004-11-11 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2) |
| BRPI0606432A2 (pt) * | 2005-01-07 | 2009-06-30 | Lexicon Pharmaceuticals Inc | anticorpos monoclonais contra angptl4 |
| US20070191322A1 (en) | 2006-02-01 | 2007-08-16 | Savage Paul B | Cationic Steroid Microbial Compositions and Methods of Use |
| JP2008247864A (ja) * | 2007-03-30 | 2008-10-16 | Univ Of Tokushima | モザイクセリンプロテアーゼ、ｍｓｐとその用途 |
| JP2008308438A (ja) * | 2007-06-14 | 2008-12-25 | Mitsubishi Tanabe Pharma Corp | 新規なインフルエンザ治療および／または予防薬 |
| EP2445963B1 (en) | 2009-06-22 | 2013-10-30 | Borealis AG | Automotive interior article with reduced smell |
| EP4083075A1 (en) * | 2012-02-15 | 2022-11-02 | CyDex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
-
2013
- 2013-04-15 BR BR112014025339A patent/BR112014025339A8/pt not_active Application Discontinuation
- 2013-04-15 NZ NZ631105A patent/NZ631105A/en unknown
- 2013-04-15 CN CN201380020133.9A patent/CN104244978A/zh active Pending
- 2013-04-15 KR KR1020147028956A patent/KR20150008383A/ko not_active Ceased
- 2013-04-15 EP EP13718744.9A patent/EP2838558A1/en not_active Ceased
- 2013-04-15 JP JP2015507076A patent/JP6446355B2/ja active Active
- 2013-04-15 HK HK15103529.7A patent/HK1202817A1/xx unknown
- 2013-04-15 WO PCT/US2013/036522 patent/WO2013158516A1/en not_active Ceased
- 2013-04-15 MX MX2014012285A patent/MX2014012285A/es active IP Right Grant
- 2013-04-15 SG SG11201405163RA patent/SG11201405163RA/en unknown
- 2013-04-15 EP EP19155349.4A patent/EP3536342A1/en not_active Withdrawn
- 2013-04-15 CA CA3219083A patent/CA3219083A1/en active Pending
- 2013-04-15 AU AU2013249577A patent/AU2013249577A1/en not_active Abandoned
- 2013-04-15 CA CA2869010A patent/CA2869010A1/en not_active Withdrawn
- 2013-04-15 US US13/862,497 patent/US9498529B2/en active Active
-
2014
- 2014-08-22 ZA ZA2014/06194A patent/ZA201406194B/en unknown
-
2017
- 2017-10-20 JP JP2017203146A patent/JP2018048169A/ja not_active Withdrawn
-
2018
- 2018-01-12 AU AU2018200265A patent/AU2018200265B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015534562A5 (enExample) | ||
| Samson et al. | Influenza virus resistance to neuraminidase inhibitors | |
| RU2019126746A (ru) | Способы лечения гриппа | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| JP2020506243A5 (enExample) | ||
| JP2014513725A5 (enExample) | ||
| HRP20230274T1 (hr) | Kemijski spojevi | |
| EA201590813A1 (ru) | Катетер для минимизации разбавления дозы во время доставки окиси азота | |
| IL321503A (en) | Recombinant virus, composition comprising the same, and uses thereof | |
| NZ601018A (en) | Ev576 for use in the treatment of viral infections of the respiratory tract | |
| JP2010285436A5 (enExample) | ||
| JP2014510130A5 (enExample) | ||
| NZ631105A (en) | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor | |
| JP2015517983A5 (enExample) | ||
| JP2010270130A5 (enExample) | ||
| BR112014007223A2 (pt) | derivados de estra-1,3,5(10),16-tetraeno-3-carboxamida, processos para sua preparação, preparações farmacêuticas compreendendo os mesmos e seu uso para preparar medicamentos | |
| BR112015018071A2 (pt) | estra-1,3,5(10),16-tetraeno-3-carboxamidas | |
| JP2014532722A5 (enExample) | ||
| JP2013533867A5 (enExample) | ||
| JP2016540000A5 (enExample) | ||
| JP2022529343A5 (enExample) | ||
| HRP20180323T1 (hr) | Derivat kromona kao antagonist dopaminskog receptora d3 za njegovu upotrebu u liječenju spektra autističnih poremećaja | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| JP2017508806A5 (enExample) | ||
| JP2018507847A5 (enExample) |